免疫抑制剂治疗顽固性葡萄膜炎的临床效果(1)
[摘要] 目的 探讨采用免疫抑制剂治疗顽固性葡萄膜炎的临床效果。 方法 随机抽取2013年1月～2015年12月我院眼科收治的100例顽固性葡萄膜炎患者作为此次研究的对象，采取抛掷硬币法将患者分为对照组和观察组，每组50例。对照组给予糖皮质激素药物治疗，观察组在糖皮质激素药物治疗的基础上加用免疫抑制剂治疗。比较两组患者的临床总有效率、视力恢复时间、用药总时间以及不良反应发生率。 结果 观察组的临床总有效率为92%，明显高于对照组的76%，差异有统计学意义(P<0.05)。与对照组比较，观察组的视力恢复时间、用药总时间均明显缩短，差异有统计学意义(P<0.05)。观察组的不良反应发生率为2%，明显低于对照组的16%，差异有统计学意义(P<0.05)。 结论 在顽固性葡萄膜炎患者的临床治疗中应用免疫抑制剂，具有显著的临床效果。
[关键词] 免疫抑制剂；顽固性葡萄膜炎；糖皮质激素
[中图分类号] R773 [文献标识码] A [文章编号] 1674-4721(2016)05(b)-0078-03
[Abstract] Objective To explore the clinical effect of using immunity inhibitor in treating stubborn intermediate uveitis. Methods 100 stubborn intermediate uveitis patients from January 2013 to December 2015 in ophtalmology department of our hospital were randomly selected as study object for this research.Patients were divided into control group and observation group by using throw coin method，and each group was 50 cases.Patients in control group were used glucocorticoid，and patients in observation group were used immunity inhibitor on the basis of glucocorticoid.The clinical total effective rate，vision recovery time，the total time of drug use and the incidence rate of adverse effects in two groups were compared. Results The clinical total effective rate in observation group was 92%，which was obvious higher than that was 76% in control group (P<0.05).Compared with control group，the vision recovery time and the total time of drug use in observation group were shorten obviously (P<0.05).The incidence rate of adverse effects in observation groups was 2%，which was obvious lower than that was 16% in control group (P<0.05). Conclusion Using immunity inhibitor in treating stubborn intermediate uveitis has obvious clinical effect.
[Key words] Immunity inhibitor；Stubborn intermediate uveitis；Glucocorticoid
葡萄膜炎是一种临床眼科较为常见的眼部病变，其发病机制较为复杂，发病人群多为青壮年人群[1-2]。顽固性葡萄膜炎是一种病情相对严重的葡萄膜炎，治疗难度大，往往累及多个系统，患者的视力也会出现明显受损[3-5]，临床治疗顽固性葡萄膜炎主要以糖皮质激素药物治疗为主，但其疗效并不十分理想[6]。故临床需寻求一种疗效更加显著的治疗方案来对顽固性葡萄膜炎进行治疗，以求能够有效改善视力，延缓病情发展。本次研究选取两组葡萄膜炎患者进行对比研究，探讨免疫抑制剂治疗顽固性葡萄膜炎的临床效果，现报道如下。
1资料与方法
1.1 一般资料
随机抽取2013年1月～2015年12月在我院眼科收治的100例顽固性葡萄膜炎患者作为此次研究的对象，所有患者均被确诊为顽固性葡萄膜炎，视力均出现一定程度的下降。此次研究经患者及其家属知情同意，且经医院伦理委员会批准通过。采取抛掷硬币法将100例患者分为对照组和观察组，每组50例患者。对照组：男30例，女20例，年龄21～56岁，平均为(38.79±15.62)岁；患病时间为1～15个月，平均为(8.23±2.21)个月。观察组：男31例，女19例，年龄20～56岁，平均为(38.56±15.49)岁；患病时间为1～16个月，平均为(8.31±2.28)个月。两组患者性别、年龄、平均患病时间比较，差异无统计学意义(P>0.05)，具有可比性。
1.2 治疗方法
对照组给予糖皮质激素药物治疗：给予患者地塞米松(生产单位：马鞍山丰原制药有限公司；批准文号：国药准字H20051748；规格：5 mg)治疗，给药方式为静脉滴注，1次/d，每次剂量为20 mg；治疗1周后，改用泼尼松(生产单位：江苏鹏鹞药业有限公司；批准文号：国药准字H32021728；规格：5 mg)治疗，给药方式为口服，1次/d，每次剂量为40 mg。, http://www.100md.com(房强 任大元)
[关键词] 免疫抑制剂；顽固性葡萄膜炎；糖皮质激素
[中图分类号] R773 [文献标识码] A [文章编号] 1674-4721(2016)05(b)-0078-03
[Abstract] Objective To explore the clinical effect of using immunity inhibitor in treating stubborn intermediate uveitis. Methods 100 stubborn intermediate uveitis patients from January 2013 to December 2015 in ophtalmology department of our hospital were randomly selected as study object for this research.Patients were divided into control group and observation group by using throw coin method，and each group was 50 cases.Patients in control group were used glucocorticoid，and patients in observation group were used immunity inhibitor on the basis of glucocorticoid.The clinical total effective rate，vision recovery time，the total time of drug use and the incidence rate of adverse effects in two groups were compared. Results The clinical total effective rate in observation group was 92%，which was obvious higher than that was 76% in control group (P<0.05).Compared with control group，the vision recovery time and the total time of drug use in observation group were shorten obviously (P<0.05).The incidence rate of adverse effects in observation groups was 2%，which was obvious lower than that was 16% in control group (P<0.05). Conclusion Using immunity inhibitor in treating stubborn intermediate uveitis has obvious clinical effect.
[Key words] Immunity inhibitor；Stubborn intermediate uveitis；Glucocorticoid
葡萄膜炎是一种临床眼科较为常见的眼部病变，其发病机制较为复杂，发病人群多为青壮年人群[1-2]。顽固性葡萄膜炎是一种病情相对严重的葡萄膜炎，治疗难度大，往往累及多个系统，患者的视力也会出现明显受损[3-5]，临床治疗顽固性葡萄膜炎主要以糖皮质激素药物治疗为主，但其疗效并不十分理想[6]。故临床需寻求一种疗效更加显著的治疗方案来对顽固性葡萄膜炎进行治疗，以求能够有效改善视力，延缓病情发展。本次研究选取两组葡萄膜炎患者进行对比研究，探讨免疫抑制剂治疗顽固性葡萄膜炎的临床效果，现报道如下。
1资料与方法
1.1 一般资料
随机抽取2013年1月～2015年12月在我院眼科收治的100例顽固性葡萄膜炎患者作为此次研究的对象，所有患者均被确诊为顽固性葡萄膜炎，视力均出现一定程度的下降。此次研究经患者及其家属知情同意，且经医院伦理委员会批准通过。采取抛掷硬币法将100例患者分为对照组和观察组，每组50例患者。对照组：男30例，女20例，年龄21～56岁，平均为(38.79±15.62)岁；患病时间为1～15个月，平均为(8.23±2.21)个月。观察组：男31例，女19例，年龄20～56岁，平均为(38.56±15.49)岁；患病时间为1～16个月，平均为(8.31±2.28)个月。两组患者性别、年龄、平均患病时间比较，差异无统计学意义(P>0.05)，具有可比性。
1.2 治疗方法
对照组给予糖皮质激素药物治疗：给予患者地塞米松(生产单位：马鞍山丰原制药有限公司；批准文号：国药准字H20051748；规格：5 mg)治疗，给药方式为静脉滴注，1次/d，每次剂量为20 mg；治疗1周后，改用泼尼松(生产单位：江苏鹏鹞药业有限公司；批准文号：国药准字H32021728；规格：5 mg)治疗，给药方式为口服，1次/d，每次剂量为40 mg。, http://www.100md.com(房强 任大元)